South-South entrepreneurial collaboration in health biotech

Thorsteinsdóttir, Halla; Melon, Christina C; Ray, Monali; Chakkalackal, Sharon; Li, Michelle; Cooper, Jan E; Chadder, J; Sáenz, Tirso W.; Paula, Maria Carlota de Souza; Kong, Wen; Li, Lexuan; Madkour, Loutfy H.; Aly, Sumarni Hamid; El-Nikhely, Nefertiti; Chaturvedi, Sachin; Konde, Victor; Daar, Abdallah S.; Сингер, Петер

doi:10.1038/nbt0510-407

Cited by 33 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is a significant development and it demonstrates that AU partner nations understand the value of research as a potential mechanism to: 1) decrease the burden of disease that affects their populations, 2) create cheaper and “home grown” alternatives to pharmacological agents that are usually purchased from high-income countries, 3) acknowledge the economic benefits that investments in research infrastructure can develop through home-grown companies, which in turn provide jobs to citizens who eventually pay taxes [2]. Local investments have occurred in many countries in the Southern Hemisphere allowing these countries to improve their economies which could be suggested as a way forward for SSA [2,15,18]. …”

Section: Challenges For Genomics Research In Africamentioning

confidence: 99%

“…We must also acknowledge that corruptions and/or mismanagement of these well-intentioned programs can perturb any advances; however, a multifaceted approach would be important to overcome the barriers expressed in the first challenge. We advocate a multitiered approach because it has been shown to have success in South and Central America and in Asia [13,15]. The multitiered approach allows for investment in several areas while also balancing competing interests.…”

Section: Challenges For Genomics Research In Africamentioning

confidence: 99%

“…This concern was recognized by the World Health Organization (WHO) over a decade ago; the WHO commissioned the report Genomics and World Health in recognition of the potential and significant positive and negative impacts genomics could have on global health [12]. A decade after the WHO report was published, large-scale investments in biotechnology and human genomic studies have been made by Mexico, India, China and Thailand producing both economic and scientific dividends which we suggest have had a beneficial effect on life expectancy [2,13-15]. Within these countries an increase in life expectancy has been observed which can be attributed to medical innovation sparked by biotechnology and genomics (large scale vaccination programs), non-medical programs (continued education, improved literacy rate of the population) and other factors [16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Biomedical research, a tool to address the health issues that affect African populations

Peprah

Wonkam

2013

Globalization and Health

View full text Add to dashboard Cite

Traditionally, biomedical research endeavors in low to middle resources countries have focused on communicable diseases. However, data collected over the past 20 years by the World Health Organization (WHO) show a significant increase in the number of people suffering from non-communicable diseases (e.g. heart disease, diabetes, cancer and pulmonary diseases). Within the coming years, WHO predicts significant decreases in communicable diseases while non-communicable diseases are expected to double in low and middle income countries in sub-Saharan Africa. The predicted increase in the non-communicable diseases population could be economically burdensome for the basic healthcare infrastructure of countries that lack resources to address this emerging disease burden. Biomedical research could stimulate development of healthcare and biomedical infrastructure. If this development is sustainable, it provides an opportunity to alleviate the burden of both communicable and non-communicable diseases through diagnosis, prevention and treatment. In this paper, we discuss how research using biomedical technology, especially genomics, has produced data that enhances the understanding and treatment of both communicable and non-communicable diseases in sub-Saharan Africa. We further discuss how scientific development can provide opportunities to pursue research areas responsive to the African populations. We limit our discussion to biomedical research in the areas of genomics due to its substantial impact on the scientific community in recent years however, we also recognize that targeted investments in other scientific disciplines could also foster further development in African countries.

show abstract

Section: Challenges For Genomics Research In Africamentioning

confidence: 99%

Section: Challenges For Genomics Research In Africamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomedical research, a tool to address the health issues that affect African populations

Peprah

Wonkam

2013

Globalization and Health

View full text Add to dashboard Cite

show abstract

“…Previous studies have evaluated the strengthening biomedical innovation landscape, increasing number of biotech companies and the innovative biotech partnerships within the emerging markets. 1,2,3 This article proposes a virtual "south-south" model -a biotech that would perform the entire value chain of R&D through a network of collaborations and funding from the emerging markets -that can potentially deliver proof-of-concept (Phase II) drug candidates more cost effectively.…”

Section: Introductionmentioning

confidence: 99%

EmergingCo: A Virtual “South-South” Biotech Model

Gautam¹

2015

JCB

View full text Add to dashboard Cite

The article proposes a “virtual” biotech model for the emerging markets - termed EmergingCo - and develops a comparative financial model to argue that such a virtual biotech can deliver drug candidates from discovery through proof-of-concept (Phase II) more cost effectively than the traditional drug development paradigm. Data from published studies on drug development costs have been compared with a cost structure model for EmergingCo using a framework where all R&D can be accomplished through a virtual network of partnerships within emerging markets. A couple of case studies from China and India are used to lend support to the cost structure model. Such a model, either as a venture backed company or a virtual unit of big pharma, could provide an alternate vehicle for delivering mid-to late stage clinical candidates, similar to Lilly's Chorus model.

show abstract

“…See other cases that provide some caveat, without altering the general picture, to the argument of this paper (Thorsteinsdóttir et al, 2010).…”

mentioning

confidence: 99%

Biotechnology: a case of delayed international convergence?

Niosi¹

2014

IJBT

View full text Add to dashboard Cite

Catching up and leapfrogging regularly occur in capitalist economies, both at the level of entire countries and specific industries. The USA has taken the lead in biopharmaceuticals and has kept it for over fifty years. Biotechnology is now helping the US pharmaceutical industry to keep its global leadership patent and product figures or biotechnology drugs indicate that the USA is keeping its lead, and is not going to be left behind by any other nation, advanced or emerging, in the foreseeable future.

show abstract

South-South entrepreneurial collaboration in health biotech

Cited by 33 publications

References 19 publications

Biomedical research, a tool to address the health issues that affect African populations

Biomedical research, a tool to address the health issues that affect African populations

EmergingCo: A Virtual “South-South” Biotech Model

Biotechnology: a case of delayed international convergence?

Contact Info

Product

Resources

About